Shelter Pharma completes USD 18,300 export order to UAE

Shelter Pharma Ltd has successfully completed the manufacturing and dispatch of an export order worth USD 18,300 to First Veterinary Medicines Trading LLC in the UAE. The order, which was received on March 12, 2026, involved the supply of Animal Healthcare products. This completion marks a significant milestone for the company, reflecting its growing global presence and commitment to delivering quality products within stipulated timelines.

The company submitted the intimation regarding this completion to BSE Limited under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The disclosure confirmed that the entire order value has been dispatched, with no balance pending.

Order Details

The following table outlines the key particulars of the transaction:

Particulars	Details
Name of Customer	First Veterinary Medicines Trading LLC., UAE
Product	Animal Healthcare Products
Order Value	USD 18,300
Manufacturing Status	Completed
Dispatch Status	Completed
Value Dispatched till Date	USD 18,300
Balance Value Pending Dispatch	Nil
Nature of Order	Export Order
Destination Country	UAE

The management emphasized that the successful execution of this international order underscores its capability to meet global demand. The filing was made by Mustaqim Nisarahmed Sabugar, Managing Director of Shelter Pharma Ltd, on July 1, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
0.0%	-12.22%	-12.67%	-23.17%	-42.05%	-39.23%

Shelter Pharma reported a 44% year-on-year increase in revenue from operations to INR 73.13 Cr for the financial year ended March 31, 2026. Profit after tax rose 25% to INR 9.03 Cr, while EBITDA increased 26% to INR 12.72 Cr. The company announced its vision to scale operations substantially and target annual revenues of around INR 200 Cr by FY30.

Financial Performance

For the full year FY26, the company achieved an EBITDA margin of 17.39% and a PAT margin of 12.3%. Return on capital employed (ROCE) stood at 26.04%, while return on equity (ROE) was 19.39%. Revenue from exports reached INR 6 Cr, marking a 164% increase in FY26. The revenue mix comprised 55% from the veterinary segment and 45% from human healthcare.

Metric	FY26 Value	YoY Growth
Revenue from Operations	INR 73.13 Cr	44%
EBITDA	INR 12.72 Cr	26%
PAT	INR 9.03 Cr	25%
EBITDA Margin	17.39%	-
PAT Margin	12.3%	-
ROCE	26.04%	-
ROE	19.39%	-

Strategic Expansion and Outlook

Management attributed the growth to a deliberate pan-India expansion and a focus on exports. The company is currently present in countries including UAE, Kuwait, Iraq, Qatar, Nepal, Bangladesh, Mauritius, Yemen, and Sudan. To support future growth, Shelter Pharma has acquired land near Ahmedabad for a second manufacturing facility. The upcoming unit is expected to significantly enhance production capacity.

The company is preparing to launch a new range of high-value nutraceutical and herbal healthcare products. Management stated that the INR 200 Cr revenue target by FY30 is based on actual numbers rather than conservative estimates, citing strong export performance and expansion into new Indian states. For the new plant, a capital expenditure of INR 12 to 15 Cr is anticipated, primarily funded through internal accruals.

Operational Details

Shelter Pharma operates with a low-debt structure and high operating efficiency. The company holds certifications including GMP, HACCP, ISO 9001, and ISO 22000. Its distribution network includes over 12,000 doctors and 5,000-plus retail pharmacies. The sales team comprises approximately 80 people across India.

Regarding margins, management indicated that export margins are roughly 20% to 25% higher than domestic margins. The company expects EBITDA margins to improve beyond 20% in the coming years as operational efficiencies from expansion stabilize. The working capital cycle, currently higher due to expansion and credit periods offered to new distributors, is being targeted for reduction to 30 days.